Andrew T Yan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3383810/publications.pdf

Version: 2024-02-01

254 papers	8,583 citations	53794 45 h-index	56724 83 g-index
262 all docs	262 docs citations	262 times ranked	10363 citing authors

#	Article	IF	Citations
1	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Heart and Vessels, 2022, 37, 1291-1298.	1.2	3
2	Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab. European Radiology, 2022, 32, 4234-4242.	4.5	3
3	Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. Acta Diabetologica, 2022, 59, 575.	2.5	4
4	Objective risk assessment vs standard care for acute coronary syndromesâ€"The Australian GRACE Risk tool Implementation Study (AGRIS): a process evaluation. BMC Health Services Research, 2022, 22, 380.	2.2	1
5	Assessments of right ventricular strain using cardiac m <scp>agnetic resonance imaging</scp> following kidney transplantation. Nephrology, 2022, 27, 371-375.	1.6	0
6	Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer. JACC: Cardiovascular Imaging, 2021, 14, 962-974.	5.3	50
7	Cardiac remodeling in middle-aged endurance athletes: relation between signal-averaged electrocardiogram and LV mass. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H316-H322.	3.2	1
8	Evaluation of left atrial remodeling in kidney transplant patients using cardiac magnetic resonance imaging. Journal of Nephrology, 2021, 34, 851-859.	2.0	3
9	Cardiac MRI assessment of the right ventricle pre-and post-kidney transplant. International Journal of Cardiovascular Imaging, 2021, 37, 1757-1766.	1.5	3
10	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Canadian Journal of Diabetes, 2021, , .	0.8	1
11	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes. JAMA Cardiology, 2021, 6, 304.	6.1	29
12	Left atrial volume and function measured by cardiac magnetic resonance imaging as predictors of shocks and mortality in patients with implantable cardioverter-defibrillators. International Journal of Cardiovascular Imaging, 2021, 37, 2259-2267.	1.5	2
13	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	8.6	19
14	Clinical risk prediction models for the prognosis and management of acute coronary syndromes. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 222-228.	4.0	2
15	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27â€‰979 Patients With Incident Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006646.	2.2	13
16	Contemporary use of guidelineâ€based higher potency P2Y12 receptor inhibitor therapy in patients with moderateâ€toâ€high risk nonâ€ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II crossâ€sectional study. Clinical Cardiology, 2021, 44, 839-847.	1.8	3
17	Awareness of Warning Symptoms of Heart Disease and Stroke: Results of a Follow-up Study of the Chinese Canadian Cardiovascular Health Project. CJC Open, 2021, 3, 741-750.	1.5	3
18	Prognostic value of cardiovascular magnetic resonance left ventricular volumetry and geometry in patients receiving an implantable cardioverter defibrillator. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 72.	3.3	3

#	Article	IF	Citations
19	Empagliflozin Reduces Myocardial Extracellular Volume in Patients WithÂType 2 Diabetes and CoronaryÂArtery Disease. JACC: Cardiovascular Imaging, 2021, 14, 1164-1173.	5.3	51
20	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. CJC Open, 2021, 3, 1419-1427.	1.5	1
21	A Novel Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Biomarker Anti-DSG2 is Absent in Athletes with Right Ventricular Enlargement. CJC Open, 2021, 3, 1413-1418.	1.5	1
22	Relationships between cardiac structural and functional assessment by cardiac MRI and hemoglobin in end-stage renal disease. Journal of Nephrology, 2021, 34, 1561-1563.	2.0	0
23	Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study. CJC Open, 2021, 3, 1463-1470.	1.5	1
24	Right Ventricular Function at Cardiac MRI Predicts Cardiovascular Events in Patients with an Implantable Cardioverter-Defibrillator. Radiology, 2021, 301, 322-329.	7.3	4
25	Exaggerated Blood Pressure Responses To Exercise: Assessment Of Criteria In Middle-aged Male Endurance Athletes. Medicine and Science in Sports and Exercise, 2021, 53, 9-10.	0.4	0
26	The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1470-1479.	4.5	11
27	Development of Acute Myocardial Infarction Mortality and Readmission Models for Public Reporting on Hospital Performance in Canada. CJC Open, 2021, 3, 1051-1059.	1.5	6
28	Atrial structure and function in middleâ€aged, physicallyâ€active males and females: A cardiac magnetic resonance study. Clinical Cardiology, 2021, 44, 1467-1474.	1.8	2
29	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. Journal of Diabetes and Its Complications, 2021, 35, 107997.	2.3	2
30	The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF). Acta Diabetologica, 2021, 58, 633-641.	2.5	2
31	Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 200.	6.8	10
32	Right Ventricular Mass 12 Years after Osteosarcoma: Multimodality Imaging with Pathologic Correlation. Radiology: Cardiothoracic Imaging, 2021, 3, e210191.	2.5	0
33	Mapping the burden of atherosclerosis: global lessons from Portugal. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 117-118.	4.0	0
34	Myocardial strain assessment using cardiovascular magnetic resonance imaging in recipients of implantable cardioverter defibrillators. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 115.	3.3	0
35	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. Journal of Cardiology, 2021, , .	1.9	2
36	The Increase in Paraoxonase 1 Is Associated With Decrease in Left Ventricular Volume in Kidney Transplant Recipients. Frontiers in Cardiovascular Medicine, 2021, 8, 763389.	2.4	2

#	Article	IF	Citations
37	Sex-Specific Differences in New York Heart Association Classification and Outcomes of Decompensated Heart Failure. Canadian Journal of Cardiology, 2020, 36, 4-6.	1.7	5
38	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2020, 141, 704-707.	1.6	225
39	Predicting Sudden Death in Dilated Cardiomyopathy: The Potential Power of Magnetic Resonance Imaging as a Critical Tool. Canadian Journal of Cardiology, 2020, 36, 1006-1008.	1.7	0
40	Cardiac MRI measurements of pericardial adipose tissue volumes in patients on in-centre nocturnal hemodialysis. Journal of Nephrology, 2020, 33, 355-363.	2.0	5
41	Cardiac Remodeling in Middle-Aged Endurance Athletes and Recreationally Active Individuals: Challenges in Defining the â€œAthlete's Heartâ€• Journal of the American Society of Echocardiography, 2020, 33, 247-249.	2.8	7
42	Stress cardiac MRI in stable coronary artery disease. Current Opinion in Cardiology, 2020, 35, 566-573.	1.8	4
43	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.7	22
44	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Journal of the American Society of Echocardiography, 2020, 33, 644-646.	2.8	18
45	Reply to Sepehrvand etÂal.â€”Promoting Enrollment of Women in Cardiovascular Clinical Trials. Canadian Journal of Cardiology, 2020, 36, 969.e9.	1.7	2
46	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabolism Open, 2020, 7, 100039.	2.9	14
47	Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. Breast Cancer Research and Treatment, 2020, 181, 155-165.	2.5	14
48	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. CJC Open, 2020, 2, 118-128.	1.5	9
49	Left Ventricular Fibrosis in Middle-Age Athletes and Physically Active Adults. Medicine and Science in Sports and Exercise, 2020, 52, 2500-2507.	0.4	10
50	Left ventricular strain analysis using cardiac magnetic resonance imaging in patients undergoing inâ€centre nocturnal haemodialysis. Nephrology, 2019, 24, 557-563.	1.6	5
51	Growth differentiation factor 15 is decreased by kidney transplantation. Clinical Biochemistry, 2019, 73, 57-61.	1.9	13
52	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
53	CMR and Tissue Characterization. Journal of the American College of Cardiology, 2019, 73, 3359.	2.8	0
54	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371

#	Article	IF	Citations
55	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metabolism, 2019, 30, 609-613.	16.2	69
56	Thiamin supplementation does not improve left ventricular ejection fraction in ambulatory heart failure patients: a randomized controlled trial. American Journal of Clinical Nutrition, 2019, 110, 1287-1295.	4.7	14
57	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e42-e44.	8.6	25
58	Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab. American Journal of Cardiology, 2019, 123, 1173-1179.	1.6	10
59	Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. Heart, 2019, 105, 1649-1655.	2.9	7
60	Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study. International Journal of Cardiovascular Imaging, 2019, 35, 2085-2093.	1.5	17
61	Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. Journal of the American Society of Nephrology: JASN, 2019, 30, 641-652.	6.1	83
62	Prevalence of Thiamin Deficiency in Ambulatory Patients with Heart Failure. Journal of the Academy of Nutrition and Dietetics, 2019, 119, 1160-1167.	0.8	3
63	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. Canadian Journal of Cardiology, 2019, 35, 160-168.	1.7	4
64	Global lessons for quality care: a tale of two countries. Heart, 2019, 105, 812-813.	2.9	3
65	Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials. Canadian Journal of Cardiology, 2019, 35, 653-660.	1.7	56
66	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. BMJ Open, 2019, 9, e032165.	1.9	27
67	Peri-Infarct Quantification by Cardiac Magnetic Resonance to Predict Outcomes in Ischemic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2019, 12, e009156.	2.6	20
68	Clinical application of echocardiographic-derived myocardial strain imaging in subclinical disease. Current Opinion in Cardiology, 2019, 34, 147-155.	1.8	5
69	Left Atrial Remodeling Assessed by Cardiac MRI after Conversion from Conventional HemodialysisÂto In-Centre Nocturnal Hemodialysis. Journal of Nephrology, 2019, 32, 273-281.	2.0	5
70	Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. International Journal of Cardiovascular Imaging, 2019, 35, 653-662.	1.5	24
71	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrology Dialysis Transplantation, 2019, 34, 339-346.	0.7	28
72	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 309-317.	1.0	6

#	Article	IF	Citations
73	Looking beyond cancer for cabozantinib-induced cardiotoxicity: evidence of absence or absence of evidence?. Annals of Translational Medicine, 2019, 7, S121-S121.	1.7	0
74	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes. Coronary Artery Disease, 2018, 29, 469-476.	0.7	4
75	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). Clinical Cardiology, 2018, 41, 285-292.	1.8	7
76	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Canadian Journal of Cardiology, 2018, 34, 736-743.	1.7	10
77	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 309-317.	4.0	12
78	Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 436-444.	4.5	25
79	Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers. Clinical Drug Investigation, 2018, 38, 341-351.	2.2	37
80	A new risk stratification tool for women with acute coronary syndrome. International Journal of Cardiology, 2018, 259, 53-54.	1.7	1
81	Trends in the incidence and outcomes of patients with aortic stenosis hospitalization. American Heart Journal, 2018, 199, 144-149.	2.7	18
82	Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. International Journal of Cardiology, 2018, 261, 228-233.	1.7	65
83	Left ventricular structure and diastolic function by cardiac magnetic resonance imaging in hypertrophic cardiomyopathy. Indian Heart Journal, 2018, 70, 75-81.	0.5	14
84	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Canadian Journal of Diabetes, 2018, 42, 130-137.	0.8	25
85	Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. Cancer, 2018, 124, 1269-1278.	4.1	20
86	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. American Journal of Cardiology, 2018, 121, 294-300.	1.6	6
87	Association between conversion to in-center nocturnal hemodialysis and right ventricular remodeling. Nephrology Dialysis Transplantation, 2018, 33, 1010-1016.	0.7	8
88	Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 83.	3.3	24
89	Determinants of Left Ventricular Characteristics Assessed by Cardiac Magnetic Resonance Imaging and Cardiovascular Biomarkers Related to Kidney Transplantation. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811880997.	1.1	13
90	Immediate non-culprit vessel percutaneous coronary intervention (PCI) in patients with acute myocardial infarction and cardiogenic shock: a swinging pendulum. Journal of Thoracic Disease, 2018, 10, 661-666.	1.4	6

#	Article	IF	Citations
91	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. Journal of the American Heart Association, 2018, 7, e009859.	3.7	60
92	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. European Heart Journal, 2018, 39, 3798-3806.	2.2	62
93	Excessive exercise in endurance athletes: Is atrial fibrillation a possible consequence?. Applied Physiology, Nutrition and Metabolism, 2018, 43, 973-976.	1.9	14
94	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2018, 122, 944-951.	1.6	11
95	Mineralocorticoid receptor antagonists for heart failure: lost in translation?. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 237-238.	4.0	0
96	Cardiac MRI and radionuclide ventriculography for measurement of left ventricular ejection fraction in ICD candidates. Magnetic Resonance Imaging, 2018, 52, 69-74.	1.8	3
97	Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. PLoS Medicine, 2018, 15, e1002501.	8.4	82
98	Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization. Journal of the American Heart Association, 2017, 6, .	3.7	52
99	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2017, 33, 737-746.	1.7	58
100	Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction. Journal of Arrhythmia, 2017, 33, 134-138.	1.2	3
101	Nutritional status after conversion from conventional to in-centre nocturnal hemodialysis. International Urology and Nephrology, 2017, 49, 1453-1461.	1.4	3
102	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. International Journal of Cardiology, 2017, 240, 30-36.	1.7	15
103	Relationships Between Left Ventricular Structure and Function According to Cardiac MRI and Cardiac Biomarkers in End-Stage Renal Disease. Canadian Journal of Cardiology, 2017, 33, 501-507.	1.7	10
104	Relationship between changes in blood pressure and left ventricular mass over 1 year in end-stage renal disease. Journal of Hypertension, 2017, 35, 1709-1716.	0.5	7
105	Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 965-973.	4.5	25
106	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 582-587.	1.6	8
107	Prognostic value of visually detected coronary artery calcification on unenhanced non-gated thoracic computed tomography for prediction of non-fatal myocardial infarction and all-cause mortality. Journal of Cardiovascular Computed Tomography, 2017, 11, 196-202.	1.3	32
108	Association Between Cardiovascular RiskÂFactors and Aortic Stenosis. Journal of the American College of Cardiology, 2017, 69, 1523-1532.	2.8	162

#	Article	IF	Citations
109	Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	9
110	Population-Based Study on Patterns of Cardiac Stress Testing After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	12
111	Bridged Bilateral Superior Venae Cavae With Direct Left Atrial Appendage Connection and No Other Congenital Cardiac Anomaly. Canadian Journal of Cardiology, 2017, 33, 1066.e13-1066.e15.	1.7	0
112	Reply. Journal of the American College of Cardiology, 2017, 70, 1104.	2.8	4
113	Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single â€œreal-worldâ€•setting. Medical Oncology, 2017, 34, 154.	2.5	16
114	Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. American Heart Journal, 2017, 193, 46-54.	2.7	2
115	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. International Journal of Cardiology, 2017, 244, 24-29.	1.7	19
116	A Randomized Control Trial Using a Validated Prediction Model for Diagnosing Acute Heart Failure in Undifferentiated Dyspneic Emergency Department Patientsâ€”Results of the GASP4Ar Study. Journal of Cardiac Failure, 2017, 23, 145-152.	1.7	7
117	Reduction of carbamylated albumin by extended hemodialysis. Hemodialysis International, 2016, 20, 510-521.	0.9	9
118	Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open, 2016, 4, E66-E72.	2.4	10
119	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 3, qcw051.	4.0	5
120	Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials. Cardiovascular Revascularization Medicine, 2016, 17, 295-301.	0.8	5
121	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. International Journal of Cardiology, 2016, 218, 291-297.	1.7	8
122	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart, 2016, 102, 1396-1402.	2.9	13
123	Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?. Diabetes Care, 2016, 39, e212-e213.	8.6	190
124	The relationship between the proportion of admitted high risk ACS patients and hospital delivery of evidence based care. International Journal of Cardiology, 2016, 222, 86-92.	1.7	3
125	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Research and Treatment, 2016, 157, 535-544.	2.5	23
126	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. American Heart Journal, 2016, 180, 82-89.	2.7	19

#	Article	IF	Citations
127	Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Nonâ€“ST-Elevation Myocardial Infarction, 2003-2013. JAMA - Journal of the American Medical Association, 2016, 316, 1073.	7.4	80
128	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. American Journal of Cardiology, 2016, 117, 754-759.	1.6	15
129	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 214-222.	1.0	11
130	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 277-284.	4.0	14
131	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. Canadian Journal of Cardiology, 2016, 32, 1221.e11-1221.e18.	1.7	7
132	The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease. Canadian Journal of Cardiology, 2016, 32, 369-377.	1.7	27
133	The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute, 2016, 108, djv301.	6.3	62
134	Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 44.	3.3	46
135	From Mars to Venus: Gender Differences in the Management and Outcomes of Acute Coronary Syndromes. Current Pharmaceutical Design, 2016, 22, 3790-3801.	1.9	5
136	Early Outgrowth Pro-Angiogenic Cell Number and Function Do Not Correlate with Left Ventricular Structure and Function in Conventional Hemodialysis Patients: A Cross-Sectional Study. Canadian Journal of Kidney Health and Disease, 2015, 2, 60.	1.1	4
137	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. Circulation, 2015, 132, 2345-2350.	1.6	42
138	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. International Journal of Cardiology, 2015, 201, 493.	1.7	2
139	Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 166-174.	2.9	39
140	Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (a Subgroup Analysis of TRANSFER-AMI). American Journal of Cardiology, 2015, 115, 1005-1012.	1.6	3
141	Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 31-36.	4.0	10
142	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2015, 31, 1455-1461.	1.7	37
143	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. Heart, 2015, 101, 1554-1561.	2.9	10
144	Relationship between different blood pressure measurements and left ventricular mass by cardiac magnetic resonance imaging in endâ€“stage renal disease. Journal of the American Society of Hypertension, 2015, 9, 275-284.	2.3	14

#	Article	IF	Citations
145	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. International Journal of Cardiology, 2015, 190, 34-39.	1.7	20
146	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). American Heart Journal, 2015, 170, 995-1004.e1.	2.7	23
147	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. European Heart Journal, 2015, 36, 976-983.	2.2	61
148	Thiamin deficiency and heart failure: the current knowledge and gaps in literature. Heart Failure Reviews, 2015, 20, 1-11.	3.9	29
149	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. Heart, 2014, 100, 1456-1461.	2.9	3
150	Efficacy of an Early Invasive Strategy After Fibrinolysis in ST-Elevation Myocardial Infarction Relative to the Extent of Coronary Artery Disease. Canadian Journal of Cardiology, 2014, 30, 1555-1561.	1.7	5
151	Benign Intramyocardial Mesothelial Cyst in the Right Ventricular Outflow Tract. Circulation, 2014, 130, e275-7.	1.6	2
152	Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management. Canadian Journal of Cardiology, 2014, 30, 869-878.	1.7	105
153	Correlates of left ventricular mass in chronic hemodialysis recipients. International Journal of Cardiovascular Imaging, 2014, 30, 349-356.	1.5	18
154	Inâ€Center Nocturnal Hemodialysis. Seminars in Dialysis, 2014, 27, 179-187.	1.3	4
155	Prognostic Implications of Prominent R Wave in Electrocardiographic Leads V1 or V2 in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2014, 113, 1962-1967.	1.6	0
156	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. Canadian Journal of Cardiology, 2014, 30, 1725-1731.	1.7	26
157	Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. American Heart Journal, 2014, 168, 757-765.e3.	2.7	6
158	Patient characteristics associated with self-presentation, treatment delay and survival following primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 214-222.	1.0	18
159	Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After) Tj ETQq1 1 0.784314 rgBT /Ove 2014, 114, 955-961.	1.6	9
160	Cardiac magnetic resonance imaging for non-invasive diagnosis of lipomatous hypertrophy of inter-atrial septum. Indian Heart Journal, 2014, 66, 244-246.	0.5	5
161	Treatment and Outcomes of Patients With Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions (Insights from the Canadian Global Registry of Acute Coronary Events [GRACE]) Tj ETQq1 1 0.784314 rgBT /O 202-207.	1.6	23
162	Management of Risk Factors Among Ambulatory Patients at High Cardiovascular Risk in Canada: A Follow-up Study. Canadian Journal of Cardiology, 2013, 29, 1586-1592.	1.7	5

#	Article	IF	Citations
163	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 350-358.	1.0	31
164	Assessment of right ventricular volumes and function using cardiovascular magnetic resonance cine imaging after atrial redirection surgery for complete transposition of the great arteries. International Journal of Cardiovascular Imaging, 2013, 29, 335-342.	1.5	13
165	Use and Timing of Coronary Angiography and Associated In-hospital Outcomes in Canadian Nonâ€“ST-Segment Elevation Myocardial Infarction Patients: Insights from the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2013, 29, 1429-1435.	1.7	20
166	Comparative Assessment of 2-Dimensional Echocardiography vs Cardiac Magnetic Resonance Imaging in Measuring Left Ventricular Mass in Patients With and Without End-Stage Renal Disease. Canadian Journal of Cardiology, 2013, 29, 384-390.	1.7	25
167	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in nonâ€“ST-segment elevation acute coronary syndromes. American Heart Journal, 2013, 166, 290-297.	2.7	20
168	Management and Outcomes of Non-ST Elevation Acute Coronary Syndromes in Relation to Previous Use of Antianginal Therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE]) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 112, 51-56.	1.6	4
169	Temporal Trends and Referral Factors for Cardiac Rehabilitation Post-Acute Coronary Syndrome in Ontario: Insights From the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2013, 29, 1604-1609.	1.7	10
170	Canada Acute Coronary Syndrome Risk Score: A new risk score for early prognostication in acute coronary syndromes. American Heart Journal, 2013, 166, 58-63.	2.7	49
171	Prognostic significance of presenting blood pressure in nonâ€“ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. American Heart Journal, 2013, 166, 716-722.	2.7	22
172	Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. International Journal of Cardiology, 2013, 168, 2720-2725.	1.7	5
173	Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis. Heart Asia, 2012, 4, 137-140.	1.1	4
174	Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. Nephrology Dialysis Transplantation, 2012, 27, 1591-1598.	0.7	23
175	Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. CKJ: Clinical Kidney Journal, 2012, 5, 124-129.	2.9	6
176	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). American Heart Journal, 2012, 164, 343-350.	2.7	7
177	Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. American Heart Journal, 2012, 163, 66-73.	2.7	168
178	The Association Between Prior Use of Aspirin and/or Warfarin and the In-hospital Management and Outcomes in Patients Presenting With Acute Coronary Syndromes: Insights From the Global Registry of Acute Coronary Events (GRACE). Canadian Journal of Cardiology, 2012, 28, 48-53.	1.7	9
179	Reperfusion Strategies and Outcomes of ST-Segment Elevation Myocardial Infarction Patients in Canada: Observations From the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). Canadian Journal of Cardiology, 2012, 28, 40-47.	1.7	14
180	Management and Outcome of Acute Coronary Syndrome Patients in Relation to Prior History of Atrial Fibrillation. Canadian Journal of Cardiology, 2012, 28, 443-449.	1.7	20

#	Article	IF	Citations
181	Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 69.	3.3	30
182	The Role of B Vitamins in the Management of Heart Failure. Nutrition in Clinical Practice, 2012, 27, 363-374.	2.4	22
183	Relation Between Previous Angiotensin-Converting Enzyme Inhibitor Use and In-Hospital Outcomes in Acute Coronary Syndromes. American Journal of Cardiology, 2012, 109, 332-336.	1.6	4
184	Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	13
185	Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrology, 2012, 13, 3.	1.8	30
186	Persistent Left Superior Vena Cava With Retrograde Drainage From the Left Atrium Into the Left Brachiocephalic Vein. Journal of the American College of Cardiology, 2011, 58, 2141.	2.8	2
187	Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early Î²-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2011, 161, 291-297.	2.7	5
188	Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for nonâ€“ST-elevation acute coronary syndromes. American Heart Journal, 2011, 162, 347-355.e1.	2.7	25
189	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Canadian Journal of Cardiology, 2011, 27, 711-715.	1.7	11
190	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with nonâ€“ST-elevation acute coronary syndromes. American Heart Journal, 2011, 161, 878-885.	2.7	8
191	Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). European Heart Journal, 2011, 32, 1994-2002.	2.2	34
192	Factors influencing underutilization of evidence-based therapies in women. European Heart Journal, 2011, 32, 1337-1344.	2.2	166
193	The management of left ventricular systolic dysfunction in patients with advanced chronic kidney disease. Journal of Nephrology, 2011, 24, 41-49.	2.0	8
194	Disparities in Management Patterns and Outcomes of Patients With Nonâ€“ST-Elevation Acute Coronary Syndrome With and Without a History of Cerebrovascular Disease. American Journal of Cardiology, 2010, 105, 1083-1089.	1.6	27
195	Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients. American Journal of Cardiology, 2010, 106, 1270-1276.	1.6	34
196	Comparison of Baseline Characteristics, Management and Outcome of Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome in Versus Not in Clinical Trials. American Journal of Cardiology, 2010, 106, 1389-1396.	1.6	35
197	Relation Between Hemoglobin Level and Recurrent Myocardial Ischemia in Acute Coronary Syndromes Detected by Continuous Electrocardiographic Monitoring. American Journal of Cardiology, 2010, 106, 1417-1422.	1.6	33
198	Optimal Medical Therapy for Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 530-537.	2.2	64

#	Article	IF	Citations
199	Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets. Diabetes Care, 2010, 33, 2558-2560.	8.6	10
200	Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. European Heart Journal, 2010, 31, 875-882.	2.2	66
201	Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2010, 31, 958-966.	2.2	10
202	Recurrent ischemia across the spectrum of acute coronary syndromes: Prevalence and prognostic significance of (Re-)infarction and ST-segment changes in a large contemporary registry. International Journal of Cardiology, 2010, 145, 15-20.	1.7	13
203	Focal caseous mitral annular calfication: Evaluation with cardiac MRI. European Journal of Radiology Extra, 2010, 73, e53-e55.	0.1	0
204	Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. American Heart Journal, 2010, 159, 40-46.	2.7	24
205	QRS prolongation in patients with acute coronary syndromes. American Heart Journal, 2010, 159, 593-598.	2.7	20
206	Evaluation of left ventricular ejection fraction in nonâ€“ST-segment elevation acute coronary syndromes and its relationship to treatment. American Heart Journal, 2010, 159, 605-611.	2.7	11
207	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. American Heart Journal, 2010, 160, 420-427.	2.7	22
208	Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). American Heart Journal, 2010, 160, 479-486.	2.7	24
209	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. American Heart Journal, 2010, 160, 855-861.	2.7	22
210	Cardiac magnetic resonance imaging of a large prolapsing left atrial myxoma causing pulmonary hypertension and syncope. Canadian Journal of Cardiology, 2010, 26, e134-e135.	1.7	3
211	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. European Heart Journal, 2009, 30, 549-557.	2.2	84
212	Applying the Evidence. Stroke, 2009, 40, 1417-1424.	2.0	64
213	Influence of Age on Use of Cardiac Catheterization and Associated Outcomes in Patients With Non-ST-Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2009, 103, 1530-1536.	1.6	67
214	The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. American Heart Journal, 2009, 158, 193-201.e5.	2.7	165
215	Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. American Heart Journal, 2009, 158, 392-399.	2.7	160
216	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in nonâ€“ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. American Heart Journal, 2009, 158, 917-924.	2.7	18

#	Article	IF	Citations
217	The differential association between various anthropometric indices of obesity and subclinical atherosclerosis. Atherosclerosis, 2009, 207, 232-238.	0.8	38
218	Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. Canadian Journal of Cardiology, 2009, 25, e370-e376.	1.7	32
219	Understanding Physicians' Risk Stratification of Acute Coronary Syndromes. Archives of Internal Medicine, 2009, 169, 372.	3.8	114
220	Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. American Journal of Cardiology, 2008, 101, 919-924.	1.6	11
221	Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with nonâ€“ST-segment elevation acute coronary syndromes. American Heart Journal, 2008, 155, 718-724.	2.7	7
222	Impact of delayed presentation on management and outcome of nonâ€“ST-elevation acute coronary syndromes. American Heart Journal, 2008, 156, 262-268.	2.7	9
223	Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. American Heart Journal, 2008, 156, 769-775.	2.7	17
224	Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes. American Heart Journal, 2008, 156, 797-803.	2.7	8
225	Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. European Journal of Heart Failure, 2008, 10, 125-128.	7.1	34
226	Use of Cardiac Catheterization for Nonâ€“ST-Segment Elevation Acute Coronary Syndromes According to Initial Risk<subtitle>Reasons Why Physicians Choose Not to Refer Their Patients</subtitle>. Archives of Internal Medicine, 2008, 168, 291.	3.8	63
227	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. European Heart Journal, 2007, 28, 1072-1078.	2.2	226
228	Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. European Heart Journal, 2007, 29, 31-37.	2.2	11
229	Management Patterns in Relation to Risk Stratification Among Patients With Nonâ€“ST Elevation Acute Coronary Syndromes. Archives of Internal Medicine, 2007, 167, 1009.	3.8	147
230	Are acute coronary syndromes risk models too complex? reply. European Heart Journal, 2007, 28, 2176-2177.	2.2	0
231	Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. American Heart Journal, 2007, 153, 500-506.	2.7	22
232	Relationship of ST elevation in lead aVR with angiographic findings and outcome in nonâ€“ST elevation acute coronary syndromes. American Heart Journal, 2007, 154, 71-78.	2.7	93
233	Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome. American Heart Journal, 2007, 154, 1108-1115.	2.7	141
234	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Canadian Journal of Cardiology, 2007, 23, 1124-1130.	1.7	25

#	Article	IF	Citations
235	Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes and Their Relation to Outcome. American Journal of Cardiology, 2007, 100, 169-174.	1.6	17
236	Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Postâ€“Myocardial Infarction Mortality. Circulation, 2006, 114, 32-39.	1.6	732
237	Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. Canadian Journal of Cardiology, 2006, 22, 115-120.	1.7	35
238	AB50-5. Heart Rhythm, 2006, 3, S105.	0.7	0
239	Plasma Matrix Metalloproteinase-9 Level Is Correlated With Left Ventricular Volumes and Ejection Fraction in Patients With Heart Failure. Journal of Cardiac Failure, 2006, 12, 514-519.	1.7	67
240	Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. American Journal of Medicine, 2006, 119, 676-683.	1.5	148
241	Age-related differences in the management and outcome of patients with acute coronary syndromes. American Heart Journal, 2006, 151, 352-359.	2.7	94
242	ST-segment depression in nonâ€“ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. American Heart Journal, 2006, 152, 270-276.	2.7	26
243	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. American Heart Journal, 2006, 152, 676-683.	2.7	43
244	Myocardial Fibroma in Gorlin Syndrome by Cardiac Magnetic Resonance Imaging. Circulation, 2006, 114, e376-9.	1.6	30
245	Characterization of Microvascular Dysfunction After Acute Myocardial Infarction by Cardiovascular Magnetic Resonance First-Pass Perfusion and Late Gadolinium Enhancement Imaging. Journal of Cardiovascular Magnetic Resonance, 2006, 8, 831-837.	3.3	60
246	Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. Annals of Internal Medicine, 2005, 142, 132.	3.9	40
247	Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both. American Journal of Cardiology, 2005, 96, 698-704.	1.6	67
248	In-Hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. American Journal of Cardiology, 2005, 96, 913-916.	1.6	108
249	Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. European Heart Journal, 2004, 25, 2006-2012.	2.2	25
250	One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	88
251	Clinical trialâ€“derived risk model may not generalize to real-world patients with acute coronary syndrome. American Heart Journal, 2004, 148, 1020-1027.	2.7	84
252	Low-molecular-weight heparins in ischemic heart disease. Current Opinion in Cardiology, 2004, 19, 309-316.	1.8	6

#	Article	IF	Citations
253	The Role of Continuous Positive Airway Pressure in the Treatment of Congestive Heart Failure. Chest, 2001, 120, 1675-1685.	0.8	66
254	Tissue Expression and Immunolocalization of Tumor Necrosis Factor-Î± in Postinfarction Dysfunctional Myocardium. Circulation, 1999, 99, 1492-1498.	1.6	353